Epigenetic alterations play central roles in chemoresistance by regulating gene expression, signaling pathways, and CSC properties

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 3 journals. Those papers have been cited 11 times in total.

Supporting evidence — 3 representative gaps

• Epigenetic regulation in cancer chemoresistance and combined therapeutic strategies (2026) · Frontiers in Cell and Developmental Biology · doi

  Epigenetic alterations play central roles in chemoresistance by regulating gene expression, signaling pathways, and CSC properties, thereby significantly affecting tumor drug sensitivity. Epigenetic drugs targeting these mechanisms, including DNMTi, HDACi, and emerging BET protein or RNA-modifying enzyme inhibitors, have shown potential to reverse resistance and enhance chemotherapy efficacy in preclinical studies and early clinical trials (Suraweera et al., 2025; Sun et al., 2023). Notably, combination strategies with conventional chemotherapeutics can intervene at multiple resistance levels, providing new avenues to overcome tumor chemoresistance. Frontiers in Cell and Developmental Biology 06 frontiersin.org Jiang et al. 10.3389/fcell.2026.1814084 that evidence

  generalfuture work
  Keywords: epigenetic chemoresistance tumor resistance alterations play central roles regulating gene expression signaling pathways properties thereby
• CRISPR-screen informed engineered T cell therapies (2026) · Frontiers in Immunology · doi

  CRISPR screens have mapped the core circuitry by which T cells achieve anti-tumor activity, repeatedly converging on JAK/STAT cytokine signaling, proximal and distal TCR/NF-kB pathways including RNA stability programs, and transcriptional/epigenetic checkpoints that shape differentiation and persistence. Looking forward, a stage-aligned, context-aware-design strategy as presented herein provides a practical approach for the selection of targets and pathways to optimally enhance T cell therapies. As dual editing of identified target combinations can integrate complementary bene- fits into T cell therapies, combinatorial editing will be an important tool in this approach. These insights provide a rational foundation for engineering adoptive cell therapies. Coupling CRISPR screen-informed enhancements with the personalized and tumor-reactive features of TIL serves as a prom- ising approach to overcome the current efficacy challenges

  generalfuture work
  Keywords: approach cell therapies crispr tumor pathways editing screens mapped core circuitry cells achieve anti activity
• Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship (2024) · Biomedicines · cited 11× · doi

  Future studies will increasingly focus on the comprehensive epigenetic profiling of TGCTs, utilizing cutting-edge single-cell epigenomics to dissect tumor heterogeneity and pinpoint epigenetic signatures critical for tumor development and progression. Under- standing the mechanisms of epigenetic plasticity that contribute to treatment resistance is paramount. This knowledge will guide the development of targeted therapies aimed at specific epigenetic alterations, offering a promising avenue to overcome resistance to conventional treatments like cisplatin. Moreover, the emergence of targeted epigenetic interventions, including DNMTi and CRISPR-based epigenome editing tools, heralds a new era of precision medicine in TGCT therapy. These approaches hold the potential to not only improve treatment outcomes but also pave the way for combination therapies that target multiple tumorigenic pathways simultaneously, thereby enhancing efficacy and preventing resistance. Biomedicines 2024, 12, 1041 15 of 21 The advancement of liquid biopsy technologies and integrative omics analyses repre- sents an important step forward in the battle against TGCTs. By harnessing the power of circulating tumor DNA (ctDNA) methylation patterns, liquid biopsies offer a non-invasive method for the early detection, ongoing monitoring, and prognosis of TGCTs, potentially revolutionizing patient management and improving outcomes. Furthermore, the employ- ment of integrative analyses that merge genomic, transcriptomic, and epigenomic data promises to provide a comprehensive understanding of TGCT biology. This holistic ap- proach not only opens new ways for the discovery of novel biomarkers but also enables the identification of some new therapeutic targets, thereby enhancing the precision and effectiveness of TGCT treatments. Together, these innovative strategies underscore the importance of a multi-faceted approach in improving diagnosis, treatment, and prognosis for TGCT patients, highlighting a future where personalized medicine becomes a reality. In conclusion, the future of TGCT research and treatment is poised at the intersection of epigenetics and personalized medicine, promising improved outcomes for patients through innovation in diagnosis, treatment, and prevention strategies.

  generalfuture work
  Keywords: epigenetic treatment tgct future tgcts tumor resistance medicine outcomes comprehensive development targeted therapies promising treatments

Questions about this gap